Enterprise Value
1.07B
Cash
83.25M
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.08%
Institutional Own.
77.31%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Mycapssa (octreotide) Details Acromegaly | Approved Quarterly sales | |
Juxtapid/Lojuxta (lomitapide) Details HoFH (Homozygous Familial Hypercholesterolemia) | Approved Quarterly sales | |
Myalept (metreleptin injections) Details GL (Generalized Lipodystrophy) | Approved Quarterly sales | |
Oleogel-S10 (AP101) Details EB (Epidermolysis bullosa), JEB (junctional epidermolysis bullosa), DEB (dystrophic epidermolysis bullosa), SJS ( Stevens-Johnson syndrome), TEN (toxic epidermal necrolysis), radiation induced dermatitis | NDA FDA meeting | |
Lomitapide Details FCS (Familial Chylomicronemia Syndrome) | Phase 2 Data readout |